Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics to Raise $10M in Private Placement

NEW YORK – Cancer Genetics said on Thursday after the close of the market that it has signed securities purchase agreements with unnamed institutional and accredited investors to raise about $10 million through the issuance of stock and warrants.

In the private placement, Rutherford, New Jersey-based Cancer Genetics will sell 2,758,624 shares of its common stock as well as warrants to purchase an additional 2,758,624 shares.

Each share of common stock and accompanying warrant are being sold at a combined offering price of $3.625. The warrants have an exercise price of $3.50 per share, are immediately excisable, and have a term of 5.5 years.

H.C. Wainwright is acting as the exclusive placement agent for the offering.

Cancer Genetics said it expects the transaction to close around Feb. 1.

The company plans to use the net proceeds from the offering for general corporate purposes, including working capital and capital expenditures. The firm expects to have access to the proceeds following the completion of its merger with StemoniX, which is subject to stockholder approval.

In early-morning trading on the Nasdaq, Cancer Genetics' stock was down 16 percent at $4.01.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.